Ketoprofen

證據等級: L5

預測適應症: 10 個

Ketoprofen: From Pain and Inflammatory Conditions to Acromesomelic Dysplasia, Hunter-Thompson Type

One-Sentence Summary

Ketoprofen is a propionic acid non-steroidal anti-inflammatory drug (NSAID), conventionally used for pain management and inflammatory conditions. The TxGNN model predicts it may be effective for Acromesomelic Dysplasia, Hunter-Thompson Type with a prediction score of 99.98%, however 0 clinical trials and 0 publications currently support this direction — indicating that the high score most likely reflects a knowledge graph topology artifact rather than a clinically actionable therapeutic opportunity.

Quick Overview

Item	Content
Original Indication	Not available (no India regulatory approval on record)
Predicted New Indication	Acromesomelic Dysplasia, Hunter-Thompson Type
TxGNN Prediction Score	99.98%
Evidence Level	L5
India Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacological information, Ketoprofen is a non-selective COX-1/COX-2 inhibitor belonging to the propionic acid NSAID class. It acts by blocking cyclooxygenase enzymes, thereby reducing the synthesis of prostaglandins (PGE2) and prostacyclins (PGI2) — key mediators of pain, fever, and inflammation. This mechanism underlies its established role in musculoskeletal and inflammatory conditions such as rheumatoid arthritis, osteoarthritis, and spondyloarthropathies.

Acromesomelic dysplasia, Hunter-Thompson type is a rare autosomal recessive skeletal dysplasia caused by loss-of-function mutations in the GDF5 (CDMP1) gene. The resulting defect in GDF5/BMP signaling disrupts chondrogenesis and skeletogenesis, producing disproportionate shortening of the middle and distal limb segments. This is a developmental genetic disease, not an inflammatory condition.

There is no established or theoretically plausible mechanistic link between Ketoprofen’s COX inhibitory activity and the GDF5/BMP morphogenetic signaling axis. The 99.98% TxGNN score most likely arises from non-specific topological clustering of skeletal disease nodes within the knowledge graph — a recognized limitation of graph-based machine learning when disease node neighborhoods overlap structurally but not biologically. This prediction should be treated as a model artifact requiring no further clinical translation effort.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Drug Interactions: Ketoprofen has 226 recorded drug interactions in the DDInter database. Key interactions by severity level are summarized below:

Severity	Interacting Drugs
Moderate	Hydrocortisone, Triamcinolone, Dexamethasone, Betamethasone, Budesonide, Acetylsalicylic acid, Metformin, Chlorpropamide, Glimepiride, Mesalazine, Balsalazide, Naltrexone, Potassium citrate, Potassium bicarbonate, Picosulfuric acid, Polyethylene glycol (3350 with electrolytes)
Minor	Famotidine, Ranitidine, Cimetidine, Linaclotide

Key warnings and contraindications are currently unavailable in this evidence pack. Please refer to the approved package insert for complete safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The top TxGNN-predicted indication — acromesomelic dysplasia, Hunter-Thompson type — has no mechanistic rationale connecting Ketoprofen’s COX inhibitory pathway to the underlying GDF5/BMP skeletal morphogenesis defect. With zero clinical trials and zero supporting publications, this is classified as an L5 prediction and likely represents a knowledge graph false positive due to skeletal disease node topology.

To proceed, the following is needed:

Resolve DG001 (Blocking): Retrieve CDSCO/TFDA package insert PDF to extract key warnings and contraindications — required before any safety pre-screening (S1 stage) can be initiated
Resolve DG002 (High): Query DrugBank API for complete MOA data to enable mechanistic relevance analysis across all predicted indications
Reprioritize candidate evaluation: Among the 10 predicted indications, Spondyloarthropathy (Rank 8, TxGNN 99.86%, Evidence Level L4) presents a substantially stronger case — NSAIDs are ASAS/EULAR first-line agents for this condition, and 1 supporting literature reference (PMID 20470931) provides indirect validation; this candidate warrants a dedicated follow-on evaluation report
India market entry assessment: Ketoprofen has no India registration on record; if repurposing development proceeds for any indication, a market feasibility analysis and regulatory pathway review will be required
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.